hVIVO PLC (AIM:HVO) chief executive Yamin 'Mo' Khan talked with Proactive's Stephen Gunnion about the company's record 2024 performance and a positive start to 2025 with the €10 million acquisition of two clinical research units in Germany from CRS. Khan highlighted achieving £63 million in revenue for 2024, a 12% increase over 2023, with industry-leading EBITDA margins of 26% and a cash position of £44 million.
The acquisition of CRS’s Mannheim and Kiel units adds 120 beds and expands hVIVO’s clinical trial offerings, diversifying services and customer reach. Khan emphasised the strategic importance of the acquisition, describing CRS as “a good fit” with a history of quality trials and strong client retention. hVIVO plans to leverage synergies between the companies to enhance patient recruitment and expand end-to-end clinical trial services.
Looking ahead, hVIVO expects 2025 revenue to reach £73 million, despite an initial dip in EBITDA margins as the company integrates CRS. Khan also confirmed the £100 million revenue goal by 2028 remains on track.
For more insights into hVIVO’s plans and progress, watch the full interview. Don’t forget to like, subscribe, and turn on notifications for updates on Proactive's channel!
#hVIVO #ClinicalResearch #PharmaNews #MedicalTrials #CEOInterview #BusinessAcquisition #ClinicalDevelopment #Biotech #HealthcareInnovation #ProactiveInvestors
